(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 82.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Connect Biopharma Holdings's revenue in 2026 is $2,953,000.On average, 10 Wall Street analysts forecast CNTB's revenue for 2026 to be $312,919,341, with the lowest CNTB revenue forecast at $12,342,965, and the highest CNTB revenue forecast at $991,845,367. On average, 10 Wall Street analysts forecast CNTB's revenue for 2027 to be $812,116,689, with the lowest CNTB revenue forecast at $0, and the highest CNTB revenue forecast at $2,744,105,515.
In 2028, CNTB is forecast to generate $1,087,692,265 in revenue, with the lowest revenue forecast at $135,772,610 and the highest revenue forecast at $2,671,370,188.